TransMedics Q4 revenue $121.6M (+50% YoY); full year net income $35.5M; 2025 guidance $530-552M

TransMedics Group, Inc.

2024-FY EPS reported $1.01 revenue$441,540,000

Q4 revenue $121.6M (+50% YoY); net income $6.9M ($0.19 EPS); full year revenue $441.5M (+83% YoY).
Full year net income $35.5M ($1.01 EPS) vs net loss $25.0M in 2023; 2025 revenue guidance $530-552M (20-25% growth).
U.S. OCS cases 3,715 in 2024 (+58% YoY); overall OCS market share 20.9% (up from 13.8% in 2023).
Independent review found no misconduct after short report allegations; submitted response to FDA Citizen Petition.
Gross margin 59.4% full year, down from 63.8% due to higher service revenue mix; cash $336.7M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.